LILRB2 and neoplasm: Specifically, LILRB2 may characterize a myeloid immunosuppression–dominant tumor microenvironment within microsatellite-stable (MSS) subtypes, offering a potential therapeutic target for overcoming the limited efficacy of immunotherapy in this group.